Securities code: Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) securities abbreviation: Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) Announcement No.: 2022017
Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937)
Performance forecast for the first quarter of 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
(I) performance forecast period: January 1, 2022 to March 31, 2022
(II) performance forecast: the expected net profit is positive
□ turning losses into profits rising in the same direction □ falling in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to shareholders of listed companies: 8-10 million yuan
Net profit: 1079300 yuan, an increase of 641.22% – 826.53% over the same period of last year
Profit after deducting non recurring profit and loss: 6 million yuan – 8 million yuan
Net profit loss: 2.7603 million yuan, an increase over the same period last year: not applicable
“10000 yuan” in this announcement refers to “10000 yuan”)
2、 Communication with accounting firms
The financial data related to this performance forecast has not been pre audited by an accounting firm. The company has made pre communication with the accounting firm on matters related to the performance forecast, and there is no difference between the company and the accounting firm on the performance forecast in the reporting period.
3、 Explanation of performance change reasons
During the reporting period, the company’s net profit attributable to shareholders of listed companies increased over the same period, mainly due to the following reasons:
The refinement of the company’s business management was improved and the precision marketing strategy continued to work. The company’s operating revenue increased steadily, an increase of about 10% over the same period last year. At the same time, the company’s profitability was enhanced and the gross profit margin increased.
4、 Other relevant instructions
This performance forecast is the preliminary calculation result of the company’s financial department, and the specific financial data will be disclosed in detail in the first quarter report of 2022. Please make careful decisions and pay attention to investment risks.
4、 Documents for future reference
Description of the board of directors on the performance forecast for the first quarter of 2022.
It is hereby announced.
Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) board of directors April 17, 2022
